People and Business: On the move
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.DR DAVID U'PRICHARD, who stepped down as chairman of research and development at SmithKline Beecham recently after only 18 months in the job, has popped up as a non-executive director of RiboTargets, a Cambridge-based biotechnology company.
Dr U'Prichard, 50, was international research director at Zeneca Pharmaceuticals between 1994 and 1997, when he moved to SmithKline Beecham.
RiboTargets was formed in July 1997 to commercialise revolutionary developments in the understanding of RNA, the link between the genetic information contained in DNA and protein synthesis.
The company is involved in developing a range of drugs to combat HIV and Hepatitis C.
E-mail: j.willcock@independent.co.uk
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments